Cullinan Oncology reports $468.3M cash; runway into H2 2026 unchanged

Cullinan Therapeutics, Inc.

Preliminary unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.
Cash runway reaffirmed through second half of 2026 based on current operating plan.
Amendment corrects original 8-K filing item number from 2.01 to 2.02; no other changes.
Preliminary estimate subject to completion of quarter-end financial close procedures.

item 2.01 item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cullinan Therapeutics, Inc. updated its as of December 31, 2023 guidance (reaffirmed).

Period: as of December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

As of December 31, 2023, the Company's unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.